 |
 |
The source of this article is Masshightech.com: http://tinyurl.com/3pxtr Signet launches new antibody for potential Parkinson’s test 09/10/2004 10:21 AM Signet Laboratories Inc. in Dedham has released its DJ-1 RUO polyclonal antibody, a potential diagnostic for predicting the emergence of Parkinson’s disease. DJ-1, a multifunctional protein implicated in many diseases such as prostate cancer and reproductive disorders, has been recently identified as causative of early-onset, autosomal recessive familial Parkinson’s disease. “Parkinson’s disease currently affects over a half-million people in the U.S. alone, with 50,000 new cases diagnosed each year,” said Richard D. Gill, president and CEO of Signet, in a statement. “Unfortunately, Parkinson’s is a very difficult disease to detect, and neurologists must rely on an evaluation of symptoms, followed by administration of anti-Parkinson’s drugs to see if the patient responds. This is a long and difficult process and sometimes leads to incorrect diagnoses that prevent a patient’s effective treatment.” Signet Laboratories is committed to developing and commercializing predictive diagnostics and preventive drugs and therapies for critical diseases. The company has a goal of diagnosing diseases prior to their full manifestation in an effort to reduce their occurrence and prevent disease progression by early identification of patients with increased risk factors. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn